Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluids.
Cancer Biomarkers have the capability to improve patient outcomes. They have potential applications in diagnosis, prognosis, monitoring of disease progression and measuring response to treatment. This type of information is particularly useful in the individualisation of treatment regimens. Biomarkers may take many forms but considerable effort has been made to identify and quantify proteins in biological fluids. However, a major challenge in measuring protein in biological fluids, such as plasma, is the sensitivity of the assay and the complex matrix of proteins present. Furthermore, determining the effect of proteases in disease requires measurement of their activity in biological fluids as quantification of the protein itself may not provide sufficient information. To date little progress has been made towards monitoring activity of proteases in plasma. The protease asparaginyl endopeptidase has been implicated in diseases such as breast cancer, leukaemia and dementia. Here we describe a new approach to sensitively and in a targeted fashion quantify asparaginyl endopeptidase activity in plasma using a synthetic substrate peptide protected from nonspecific hydrolysis using D-amino acids within the structure. Our selected reaction monitoring approach enabled asparaginyl endopeptidase activity to be measured in human plasma with both a high dynamic range and sensitivity. This manuscript describes a paradigm for future development of assays to measure protease activities in biological fluids as biomarkers of disease.
Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.|Tata Translational Cancer Research Centre, Kolkata, India.
Anindita
A
Dutta
Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
David N
DN
Potier
Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Michael J
MJ
Walker
Stoller Biomarker Discovery Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Oliver J
OJ
Gray
Children's Cancer Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Catriona
C
Parker
Children's Cancer Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Mark
M
Holland
Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Andrew J K
AJ
Williamson
Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Andrew
A
Pierce
Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.|Current address: Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals NHS Foundation Trust and Institute of Human Development, University of Manchester, Manchester, UK.
Richard D
RD
Unwin
Tata Translational Cancer Research Centre, Kolkata, India.
Shekhar
S
Krishnan
Tata Translational Cancer Research Centre, Kolkata, India.|Children's Cancer Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Vaskar
V
Saha
Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.|Stoller Biomarker Discovery Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Anthony D
AD
Whetton
D000293:Adolescent; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D001826:Body Fluids / Q000201:enzymology*; D002648:Child; D002675:Child, Preschool; D002853:Chromatography, Liquid; D003546:Cysteine Endopeptidases / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007223:Infant; D013058:Mass Spectrometry / Q000379:methods; D010455:Peptides / Q000378:metabolism; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000175:diagnosis / Q000201:enzymology*; D011994:Recombinant Proteins / Q000378:metabolism; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D000099240:Asparaginyl Endopeptidase
D014408:Biomarkers, Tumor; D003546:Cysteine Endopeptidases; D010455:Peptides; D011994:Recombinant Proteins; D000099240:Asparaginyl Endopeptidase
AEP; SRM; biomarker; legumain; protease
J Proteomics. 2010 Jan 3;73(3):629-36
19619681
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1229-39
19041286
Breast Cancer Res Treat. 2007 Mar;102(1):1-6
17028987
Biochem J. 2000 Dec 1;352 Pt 2:327-34
11085925
FEBS Lett. 1998 Dec 28;441(3):361-5
9891971
Mol Cell Proteomics. 2003 Oct;2(10):1096-103
12917320
Cancer Res. 2003 Jun 1;63(11):2957-64
12782603
Mol Cell Proteomics. 2008 Mar;7(3):509-18
17986438
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D270-2
16381862
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S152-7
12586109
Anal Chem. 2012 Jul 3;84(13):5604-10
22762262
Urol Oncol. 2002 Sep-Oct;7(5):195-8
12644216
Biochem J. 1999 May 1;339 ( Pt 3):743-9
10215615
Asian Pac J Cancer Prev. 2014;15(24):10773-7
25605174
Mol Cell Proteomics. 2002 Nov;1(11):845-67
12488461
Mol Biochem Parasitol. 2002 Apr 30;121(1):99-105
11985866
Mass Spectrom Rev. 2005 Nov-Dec;24(6):887-917
15599948
J Biol Chem. 1997 Mar 21;272(12):8090-8
9065484
Blood. 2011 Jul 21;118(3):638-49
21606482
J Natl Cancer Inst. 2014 Apr;106(4):dju012
24610907
J Proteome Res. 2005 Jul-Aug;4(4):1073-85
16083256
World J Urol. 2013 Apr;31(2):359-64
23124822
J Biol Chem. 2013 Jun 14;288(24):17495-507
23640887
J Clin Invest. 2009 Jul;119(7):1964-73
19509471
Cancer Res. 2006 Jan 15;66(2):970-80
16424032
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8167-72
16702559
Eur J Cancer. 2015 Jan;51(1):9-17
25466510
Braz J Med Biol Res. 2004 Jul;37(7):963-8
15264002